Changes in postoperative recurrence and prognostic risk factors for patients with gastric cancer who underwent curative gastric resection during different time periods

Annals of Surgical Oncology

Volumn 20, Issue 7, 2013, Pages 2317-2327

  Kim, Dae Hoon ^a   Kim, Su Mi ^b   Hyun, Jung Kuk ^b   Choi, Min Gew ^b   Noh, Jae Hyung ^b   Sohn, Tae Sung ^b   Bae, Jae Moon ^b   Kim, Sung ^b  

^a Chungbuk National University Hospital   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PROGNOSIS; RISK FACTOR; STOMACH CANCER; SURVIVAL RATE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD VESSELS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GASTRECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; LYMPHATIC VESSELS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PERIPHERAL NERVES; RISK FACTORS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR BURDEN; YOUNG ADULT;

EID: 84878822513     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2700-0     Document Type: Article

References (48)

1. Jung KW, Won YJ, Park S, et al. Cancer statistics in Korea: incidence, mortality and survival in 2005. J Korean Med Sci. 2009;24:995-1003.
2. Onate-Ocana LF, Aiello-Crocifoglio V, Mondragon-Sanchez R, Ruiz-Molina JM. Survival benefit of D2 lymphadenectomy in patients with gastric adenocarcinoma. Ann Surg Oncol. 2000;7:210-7. (Pubitemid 30215160)
3. Kim JP. Surgical results in gastric cancer. Semin Surg Oncol. 1999;17:132-8.
4. van de Velde CJ. Resection for gastric cancer in the community. Semin Oncol. 2005;32:S90-3. (Pubitemid 43080925)
5. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810-20. (Pubitemid 350044801)
6. Kim JP, Kim YW, Yang HK, Noh DY. Significant prognostic factors by multivariate analysis of 3926 gastric cancer patients. World J Surg. 1994;18:872-7; discussion 7-8.
7. Siewert JR, Bottcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228:449-61. (Pubitemid 30194389)
8. Shiraishi N, Sato K, Yasuda K, Inomata M, Kitano S. Multivariate prognostic study on large gastric cancer. J Surg Oncol. 2007;96:14-8. (Pubitemid 47015443)
9. Saito H, Osaki T, Murakami D, et al. Macroscopic tumor size as a simple prognostic indicator in patients with gastric cancer. Am J Surg. 2006;192:296-300. (Pubitemid 44223379)
10. Maruyama K. The most important prognostic factors for gastric cancer patients: a study using univariate and multivariate analyses. Scand J Gastroenterol Suppl. 1987;22:63-8. (Pubitemid 17112517)
11. Kunisaki C, Makino H, Takagawa R, et al. Tumor diameter as a prognostic factor in patients with gastric cancer. Ann Surg Oncol. 2008;15:1959-67.
12. Tianhang L, Guoen F, Jianwei B, Liye M. The effect of perineural invasion on overall survival in patients with gastric carcinoma. J Gastrointest Surg. 2008;12:1263-7.
13. Dicken BJ, Graham K, Hamilton SM, et al. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. Ann Surg. 2006;243:64-73. (Pubitemid 43054056)
14. Tokunaga M, Hiki N, Fukunaga T, Ohyama S, Yamaguchi T, Nakajima T. Better 5-year survival rate following curative gastrectomy in overweight patients. Ann Surg Oncol. 2009;16:3245-51.
15. del Casar JM, Corte MD, Alvarez A, et al. Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. J Cancer Res Clin Oncol. 2008;134:153-61. (Pubitemid 350234059)
16. Hyung WJ, Lee JH, Choi SH, Min JS, Noh SH. Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol. 2002;9:562-7. (Pubitemid 34774417)
17. Scartozzi M, Galizia E, Verdecchia L, et al. Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patients. Br J Cancer. 2006;95:445-9. (Pubitemid 44232552)
18. Ito Y, Ohno Y, Rachet B, Coleman MP, Tsukuma H, Oshima A. Cancer survival trends in Osaka, Japan: the influence of age and stage at diagnosis. Jpn J Clin Oncol. 2007;37:452-8. (Pubitemid 47249483)
19. Sim YK, Kim CY, Jeong YJ, Kim JH, Hwang Y, Yang DH. Changes of the clinicopathological characteristics and survival rates of gastric cancer with gastrectomy: 1990s vs. early 2000s. J Korean Gastric Cancer Assoc 2008. 2009;9:200-6.
20. Japanese Gastric Cancer. A Japanese classification of gastric carcinoma - 2nd english ed. Gastric Cancer. 1998;1:10-24.
21. Association JGC. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113-23.
22. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC cancer staging manual. 6th ed. New York: Springer; 2002:89-99.
23. Kim DH, Oh SJ, Oh CA, et al. The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol. 2011;104:585-91.
24. Pourhoseingholi MA, Moghimi-Dehkordi B, Safaee A, Hajizadeh E, Solhpur A, Zali MR. Prognostic factors in gastric cancer using log-normal censored regression model. Indian J Med Res. 2009;129:262-7.
25. Bani-Hani KE. Clinicopathological comparison between young and old age patients with gastric adenocarcinoma. Int J Gastrointest Cancer. 2005;35:43-52. (Pubitemid 40458579)
26. Santoro R, Carboni F, Lepiane P, Ettorre GM, Santoro E. Clinicopathological features and prognosis of gastric cancer in young European adults. Br J Surg. 2007;94:737-42. (Pubitemid 46910068)
27. Yokoyama H, Nakanishi H, Kodera Y, et al. Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fluorescent protein-tagged human gastric cancer cell line. Clin Cancer Res. 2006;12:361-8. (Pubitemid 43166122)
28. Degiuli M, Sasako M, Ponti A, Calvo F. Survival results of a multicentre phase II study to evaluate D2 gastrectomy for gastric cancer. Br J Cancer. 2004;90:1727-32. (Pubitemid 38725642)
29. Lai JF, Kim S, Li C, et al. Clinicopathologic characteristics and prognosis for young gastric adenocarcinoma patients after curative resection. Ann Surg Oncol. 2008;15:1464-9.
30. Park JC, Lee YC, Kim JH, et al. Clinicopathological aspects and prognostic value with respect to age: an analysis of 3,362 consecutive gastric cancer patients. J Surg Oncol. 2009;99:395-401.
31. Kim JP, Lee JH, Kim SJ, Yu HJ, Yang HK. Clinicopathologic characteristics and prognostic factors in 10 783 patients with gastric cancer. Gastric Cancer. 1998;1:125-33.
32. Wang X, Wan F, Pan J, Yu GZ, Chen Y, Wang JJ. Prognostic value of the ratio of metastatic lymph nodes in gastric cancer: an analysis based on a Chinese population. J Surg Oncol. 2009;99:329-34.
33. Lee WJ, Lee WC, Houng SJ, et al. Survival after resection of gastric cancer and prognostic relevance of systematic lymph node dissection: twenty years experience in Taiwan. World J Surg. 1995;19:707-13.
34. Park CH, Song KY, Kim SN. Treatment results for gastric cancer surgery: 12 years' experience at a single institute in Korea. Eur J Surg Oncol. 2008;34:36-41. (Pubitemid 350296760)
35. Kooby DA, Suriawinata A, Klimstra DS, Brennan MF, Karpeh MS. Biologic predictors of survival in node-negative gastric cancer. Ann Surg. 2003;237:828-35; discussion 35-7.
36. Yu JW, Wu JG, Zheng LH, Zhang B, Ni XC, Li XQ, Jiang BJ. Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma. J Exp Clin Cancer Res. 2009;28:55.
37. Setala LP, Kosma VM, Marin S, Lipponen PK, Eskelinen MJ, Syrjanen KJ, Alhava EM. Prognostic factors in gastric cancer: the value of vascular invasion, mitotic rate and lymphoplasmacytic infiltration. Br J Cancer. 1996;74:766-72. (Pubitemid 26300769)
38. Maehara Y, Kabashima A, Koga T, Tokunaga E, Takeuchi H, Kakeji Y, Sugimachi K. Vascular invasion and potential for tumor angiogenesis and metastasis in gastric carcinoma. Surgery. 2000;128:408-16.
39. Li JH, Zhang SW, Liu J, Shao MZ, Chen L. Review of clinical investigation on recurrence of gastric cancer following curative resection. Chin Med J (Engl). 2012;125:1479-95.
40. Roviello F, Marrelli D, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, De Stefano A. Prospective study of peritoneal recurrence after curative surgery for gastric cancer. Br J Surg. 2003;90:1113-9. (Pubitemid 37152170)
41. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359:453-62.
42. Di Costanzo F, Gasperoni S, Manzione L, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100:388-98. (Pubitemid 351480516)
43. Kulig J, Kolodziejczyk P, Sierzega M, et al. Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology. 2010;78:54-61.
44. Mari E, Floriani I, Tinazzi A, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente). Ann Oncol. 2000;11:837-43.
45. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729-37.
46. Valentini V, Cellini F, Minsky BD, et al. Survival after radiotherapy in gastric cancer: systematic review and meta-analysis. Radiother Oncol. 2009;92:176-83.
47. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-30.
48. Lee J, Lim do H, Kim S, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30:268-73.